Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrin S Reiners

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Theranostics|September 20, 2019
Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53Maximiliane Schuldner, Bastian Dörsam, Olga Shatnyeva, et al.
International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Blood|November 3, 2012
Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factorNina Reinart, Phuong-Hien Nguyen, Jorge Boucas, et al.
Oncotarget|April 23, 2016
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitroHinrich P Hansen, Ahmad Trad, Maria Dams, et al.
International Journal of Cancer|September 2, 2022
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progressionTheophilos Tzaridis, Johannes Weller, Daniel Bachurski, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventionsAndreas E Kremer, Remco van Dijk, Pamela Leckie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trialsKarolin Behringer, Horst Mueller, Helen Goergen, et al.
Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.
Oncoimmunology|February 16, 2017
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patientsSylvie Rusakiewicz, Aurélie Perier, Michaela Semeraro, et al.
Nature Genetics|November 2, 2010
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Victor Enciso-Mora, Peter Broderick, Yussanne Ma, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Theranostics|September 20, 2019
Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53Maximiliane Schuldner, Bastian Dörsam, Olga Shatnyeva, et al.
International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Blood|November 3, 2012
Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factorNina Reinart, Phuong-Hien Nguyen, Jorge Boucas, et al.
Oncotarget|April 23, 2016
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitroHinrich P Hansen, Ahmad Trad, Maria Dams, et al.
International Journal of Cancer|September 2, 2022
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progressionTheophilos Tzaridis, Johannes Weller, Daniel Bachurski, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventionsAndreas E Kremer, Remco van Dijk, Pamela Leckie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trialsKarolin Behringer, Horst Mueller, Helen Goergen, et al.
Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.
Oncoimmunology|February 16, 2017
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patientsSylvie Rusakiewicz, Aurélie Perier, Michaela Semeraro, et al.
Nature Genetics|November 2, 2010
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Victor Enciso-Mora, Peter Broderick, Yussanne Ma, et al.
Pageof 4